Meuser Commends President Trump for Extending Most Favored Nation Drug Pricing to All State Medicaid Programs

WASHINGTON, D.C. — Today, Congressman Dan Meuser (PA-09) released the following statement commending President Donald Trump, Secretary of Health Robert Kennedy Jr., and Administrator Mehmet Oz on rolling out Most Favored Nation (MFN) drug pricing to Medicaid beneficiaries in all 50 states.

Last May, President Trump signed an executive order requiring pharmaceutical manufacturers to offer their products in the United States at the same low price offered in other nations. Since then, the Trump Administration has secured agreements with 26 major pharmaceutical companies to offer nearly 90% of branded pharmaceutical products on the market at MFN pricing. The deals cover a variety of drugs and deliver significant cost reductions, including an 88% decrease in the cost of multiple sclerosis medication, a 90% decrease in the cost of Hepatitis C medication, and an 81% decrease in the cost of diabetes medicines.

So far, MFN pricing has been accessible to consumers via TrumpRx, which connects consumers directly to pharmaceutical companies to purchase prescription drugs at MFN pricing. Today’s announcement expands MFN pricing to Medicaid beneficiaries in all 50 states through the Center for Medicare and Medicaid Innovation GENEROUS Model, which requires manufacturers to provide supplemental rebates to states to align Medicaid drug prices with what other countries pay. The Council of Economic Advisors estimates that today’s announcement will save Medicaid a total of $64.3 billion over the next decade. The federal government would save $36.6 billion, while the states would save the remaining $27.6 billion.

“Today’s announcement marks an important milestone in expanding Most Favored Nation drug pricing to Americans nationwide,” said Congressman Meuser. “Pennsylvanians who are on Medicaid will now see a substantial reduction in their drug pricing due to the policies of the Trump Administration. We can continue to build on this success by passing my Most Favored Patient Act, which would lock in MFN savings for years to come and ensure that all Americans can purchase drugs at lower prices.”

Congressman Meuser has led the effort in Congress to codify the MFN drug pricing deals that the Trump Administration has secured through the Most Favored Patient Act. This legislation would codify the 26 existing MFN drug pricing deals and establish a permanent framework to codify and enforce future cost-saving healthcare agreements as they are reached. This legislation would lock in at least $600 billion in savings for the American people.

During last year’s State of the Union Address, President Trump called on Congress to codify the existing MFN and included it in his Great Healthcare Plan, which would lower drug prices and premiums for all Americans.